US Anesthesia Drugs Market Prospects Discussed in New Research Report Published at

24 May 2012 • by Natalie Aster

LONDON – The U.S. general anesthesia market is poised to grow from last year’s USD 2 billion to USD 2.3 billion by 2015, at a CAGR of close to 4%. Intravenous anesthetic drugs accounted for the largest share (65%) of the U.S. general anesthetics drugs market in 2011.

Ketamine, an anesthetic drug mainly used for initiation and maintenance of general anesthesia in humans, has been in the market for the past 41 years. There are four major players of ketamine in the U.S. market. JHP Pharmaceuticals is the only company which offers a branded generic of ketamine – ketalar. Ketalar is expected to maintain its position in the market in the coming five years but with a decreasing market share, due to high cost compared to the generic counterparts.

New research report “Anesthesia Drugs Market (2011 - 2015) - U.S. Market Entry Study” prepared by MarketsandMarkets has been recently published by Market Publishers Ltd.

Report Details:

Anesthesia Drugs Market (2011 - 2015) - U.S. Market Entry Study
Published: May, 2012
Pages: 164
Price: US$ 4.650,00

The research report offers a comprehensive guide the anesthesia drugs market, with a special focus on the ketamine market in the U.S. To contribute to a better understanding of the sector, the study gives detailed insights into major market drivers, challenges, opportunities, and key issues. Moreover, the competitive landscape along with elaborate profiles of top companies analyzed through a company overview, key financials, products & services, strategy and developments can also be found in the study.

Companies mentioned include: Abbott laboratories (U.S.), Astrazeneca Plc. (U.K.), Baxter International Inc. (U.S.), Bedford Laboratories (U.S.), Bioniche Pharmaceuticals (U.S.), Eisai Co. Ltd. (Japan), Hospira Inc. (U.S.) and JHP Pharmaceuticals (U.S.).

More new research reports by the publisher can be found at MarketsandMarkets page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970